The eye as an anatomical structure is an extremely protected organ. Most ophthalmic diseases are usually treated with topically administered drug formulations (e.g. eye drops).
Their main disadvantage is the short time of contact with the eye, which leads to a low degree of absorption of the active substance (less than 5% of the drug administered).
Attaching Lipids to Protein Based Drugs Improves Drug Delivery
Lipid molecules are attached to peptides for targeting drug delivery.
Advertisement
‘A dramatic increase of in the number of patented nanosized ophthalmic drug delivery systems have been witnessed.’
Tweet it Now
This requires frequent instillation, which usually leads to a high systemic exposure. In this regard, providing an optimal bioavailability in the eye tissues, resulting in the desired therapeutic effect represents a major challenge.
The purpose of this review is to indicate how nano- and microcarriers of drug substances can solve the problems with the drug delivery in the ocular tissues, to indicate the possible hazards and side effects, depending on the polymer nature and route of administration, and to visualize the future potential of these carriers in the pharmaceutical practice.
![Microscopic Magnetic Crystals Could be the Future of Targeted Drug Delivery]( "Microscopic Magnetic Crystals Could be the Future of Targeted Drug Delivery")
Microscopic crystals could soon be zipping drugs around your body, taking them to diseased organs, revealed a study.
Nanocarriers may (i) improve solubility (of nanosuspensions, and microemulsions); (ii) improve permeability and; (iii) provide a better prevention from metabolism and elimination (through polymer conjugation, and mucoadhesive polymers),; (iv) enhance drug stability; and (v) improve pharmacokinetics of the drug used. However, each one of these types of nanoformulations is characterized by some drawbacks. The additional combination of two drug delivery systems, i.e., nanoparticles in an in-situ gel or in contact lens, may increase the positives and decrease the disadvantages of these drug delivery systems.
The assessment of potential health hazards for the use of nanoparticles as ophthalmic drug delivery systems is based on the properties or the toxicity of the bulk material, the characteristics and properties of the nanoparticles obtained and the route of their administration. The study, regarding the safety and cytotoxicity of nanoparticles, should be specific and thorough in the context of the patho-anatomical and pathophysiological characteristics of the eye as a target organ.
Over the last years, we have witnessed a dramatic increase of in the number of patented nanosized ophthalmic drug delivery systems. The undeniable advantages that these systems provide, as in terms of improved precorneal residence time and ocular penetration, a sustained drug release, a reduced administration frequency and a higher patient compliance, give us grounds to believe that in the next few years some of these patented system will find their place on in the ophthalmic drug market.
Source: Eurekalert
Microscopic Magnetic Crystals Could be the Future of Targeted Drug Delivery
Microscopic crystals could soon be zipping drugs around your body, taking them to diseased organs, revealed a study.
Advertisement
Nanocarriers may (i) improve solubility (of nanosuspensions, and microemulsions); (ii) improve permeability and; (iii) provide a better prevention from metabolism and elimination (through polymer conjugation, and mucoadhesive polymers),; (iv) enhance drug stability; and (v) improve pharmacokinetics of the drug used. However, each one of these types of nanoformulations is characterized by some drawbacks. The additional combination of two drug delivery systems, i.e., nanoparticles in an in-situ gel or in contact lens, may increase the positives and decrease the disadvantages of these drug delivery systems.
The assessment of potential health hazards for the use of nanoparticles as ophthalmic drug delivery systems is based on the properties or the toxicity of the bulk material, the characteristics and properties of the nanoparticles obtained and the route of their administration. The study, regarding the safety and cytotoxicity of nanoparticles, should be specific and thorough in the context of the patho-anatomical and pathophysiological characteristics of the eye as a target organ.
Over the last years, we have witnessed a dramatic increase of in the number of patented nanosized ophthalmic drug delivery systems. The undeniable advantages that these systems provide, as in terms of improved precorneal residence time and ocular penetration, a sustained drug release, a reduced administration frequency and a higher patient compliance, give us grounds to believe that in the next few years some of these patented system will find their place on in the ophthalmic drug market.
Source: Eurekalert
New Approaches and Innovations in Ocular Drug Delivery Systems
A special issue on ocular drug delivery has been published in the journal Drug Delivery and Translational Research.
Advertisement
 Imaging Data Predicts Nanomedicine Drug Delivery Inside the Cancer TissuesScientists find imaging data to be useful in predicting drug delivery in tumor patients. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
A group of scientists were awarded £1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.
Is there a connection between Osteoporosis and dementia? Yes, loss in bone density may be linked to an increased risk of dementia in older age.
Link between chromosome length and biological aging marker discovered. The finding helps explain why people with longer telomeres have a lower dementia risk.
Integrated structural biology helps discover how the cystic fibrosis transmembrane conductance regulator (CFTR) works.
Link between advanced paternal age and higher risks for reproductive and offspring medical problems has been discovered.